Medidata, a Dassault Systèmes brand, has introduced Medidata Oncology Solutions and Medidata Vaccine Solutions to streamline Phase II and Phase III trials. These bundled solutions integrate key trial components to reduce complexity, accelerate decision-making, and improve assessments of treatment efficacy and safety in oncology and vaccine research.
Addressing Challenges in Oncology and Vaccine Trials
According to Joseph Schmidt, chief operating officer at Medidata, oncology and vaccine trials face challenges in recruiting diverse patients, ensuring rapid execution, and maintaining patient safety. The new bundled capabilities aim to address these issues by leveraging Medidata’s experience and expertise in these therapeutic areas.
Integrated Data Ecosystem
Both solutions deliver a unified data ecosystem by integrating Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata Clinical Data Studio, and Health Record Connect. This integration supports patient-centered endpoints, adaptive trial designs, and trial diversity, aligning with FDA guidance.
Medidata has extensive experience in oncology and vaccine trials, having conducted approximately 9,000 oncology studies and 750 vaccine trials. In 2023, 93% of oncology drug approvals went through Medidata. The company also supported hundreds of trials during the COVID-19 pandemic, including the development of mRNA vaccines.
